nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Herpes virus infection—Procarbazine—brain cancer	0.0172	0.0662	CcSEcCtD
Carfilzomib—Disease progression—Carmustine—brain cancer	0.0137	0.0527	CcSEcCtD
Carfilzomib—PSMB8—Podofilox—Etoposide—brain cancer	0.00939	1	CbGdCrCtD
Carfilzomib—PSMB10—endocrine gland—brain cancer	0.00767	0.0427	CbGeAlD
Carfilzomib—PSMB10—head—brain cancer	0.00757	0.0421	CbGeAlD
Carfilzomib—Haemorrhage intracranial—Temozolomide—brain cancer	0.00703	0.0271	CcSEcCtD
Carfilzomib—PSMB5—telencephalon—brain cancer	0.00692	0.0385	CbGeAlD
Carfilzomib—PSMB10—central nervous system—brain cancer	0.00691	0.0385	CbGeAlD
Carfilzomib—PSMB10—cerebellum—brain cancer	0.00675	0.0376	CbGeAlD
Carfilzomib—PSMB8—pituitary gland—brain cancer	0.00638	0.0355	CbGeAlD
Carfilzomib—Lopinavir—CYP2C9—brain cancer	0.00622	0.543	CrCbGaD
Carfilzomib—PSMB1—telencephalon—brain cancer	0.00605	0.0337	CbGeAlD
Carfilzomib—PSMB2—telencephalon—brain cancer	0.0059	0.0328	CbGeAlD
Carfilzomib—Hypomagnesaemia—Hydroxyurea—brain cancer	0.00581	0.0224	CcSEcCtD
Carfilzomib—PSMB5—pituitary gland—brain cancer	0.00563	0.0314	CbGeAlD
Carfilzomib—Lymphopenia—Temozolomide—brain cancer	0.00563	0.0217	CcSEcCtD
Carfilzomib—PSMB10—brain—brain cancer	0.00549	0.0305	CbGeAlD
Carfilzomib—PSMB5—medulla oblongata—brain cancer	0.00544	0.0303	CbGeAlD
Carfilzomib—Ritonavir—CYP2C9—brain cancer	0.00523	0.457	CrCbGaD
Carfilzomib—PSMB1—gonad—brain cancer	0.00505	0.0281	CbGeAlD
Carfilzomib—PSMB5—midbrain—brain cancer	0.00497	0.0277	CbGeAlD
Carfilzomib—PSMB2—gonad—brain cancer	0.00492	0.0274	CbGeAlD
Carfilzomib—PSMB1—pituitary gland—brain cancer	0.00492	0.0274	CbGeAlD
Carfilzomib—PSMB5—spinal cord—brain cancer	0.00485	0.027	CbGeAlD
Carfilzomib—PSMB2—pituitary gland—brain cancer	0.0048	0.0267	CbGeAlD
Carfilzomib—PSMB1—medulla oblongata—brain cancer	0.00475	0.0265	CbGeAlD
Carfilzomib—PSMB2—medulla oblongata—brain cancer	0.00464	0.0258	CbGeAlD
Carfilzomib—PSMB1—midbrain—brain cancer	0.00434	0.0242	CbGeAlD
Carfilzomib—PSMB2—midbrain—brain cancer	0.00424	0.0236	CbGeAlD
Carfilzomib—PSMB1—spinal cord—brain cancer	0.00424	0.0236	CbGeAlD
Carfilzomib—PSMB2—spinal cord—brain cancer	0.00413	0.023	CbGeAlD
Carfilzomib—Renal failure—Lomustine—brain cancer	0.00413	0.0159	CcSEcCtD
Carfilzomib—PSMB5—cerebellum—brain cancer	0.00384	0.0214	CbGeAlD
Carfilzomib—PSMB1—endocrine gland—brain cancer	0.00381	0.0212	CbGeAlD
Carfilzomib—PSMB1—head—brain cancer	0.00377	0.021	CbGeAlD
Carfilzomib—PSMB2—endocrine gland—brain cancer	0.00372	0.0207	CbGeAlD
Carfilzomib—PSMB2—head—brain cancer	0.00367	0.0205	CbGeAlD
Carfilzomib—PSMB8—brain—brain cancer	0.00353	0.0197	CbGeAlD
Carfilzomib—PSMB1—central nervous system—brain cancer	0.00344	0.0191	CbGeAlD
Carfilzomib—PSMB1—cerebellum—brain cancer	0.00336	0.0187	CbGeAlD
Carfilzomib—PSMB2—central nervous system—brain cancer	0.00335	0.0187	CbGeAlD
Carfilzomib—PSMB2—cerebellum—brain cancer	0.00328	0.0182	CbGeAlD
Carfilzomib—PSMB5—brain—brain cancer	0.00312	0.0174	CbGeAlD
Carfilzomib—Infection—Carboplatin—brain cancer	0.00304	0.0117	CcSEcCtD
Carfilzomib—Hepatic failure—Hydroxyurea—brain cancer	0.00298	0.0115	CcSEcCtD
Carfilzomib—Leukopenia—Lomustine—brain cancer	0.00294	0.0113	CcSEcCtD
Carfilzomib—Renal failure acute—Hydroxyurea—brain cancer	0.0029	0.0112	CcSEcCtD
Carfilzomib—PSMB1—brain—brain cancer	0.00273	0.0152	CbGeAlD
Carfilzomib—Pneumonia—Procarbazine—brain cancer	0.00268	0.0103	CcSEcCtD
Carfilzomib—PSMB2—brain—brain cancer	0.00266	0.0148	CbGeAlD
Carfilzomib—Infection—Lomustine—brain cancer	0.00266	0.0103	CcSEcCtD
Carfilzomib—Thrombocytopenia—Lomustine—brain cancer	0.00262	0.0101	CcSEcCtD
Carfilzomib—Pain—Carboplatin—brain cancer	0.00262	0.0101	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Procarbazine—brain cancer	0.00261	0.0101	CcSEcCtD
Carfilzomib—Sepsis—Carmustine—brain cancer	0.00259	0.00998	CcSEcCtD
Carfilzomib—Anorexia—Lomustine—brain cancer	0.00255	0.00984	CcSEcCtD
Carfilzomib—Blood creatinine increased—Hydroxyurea—brain cancer	0.00251	0.00967	CcSEcCtD
Carfilzomib—Body temperature increased—Carboplatin—brain cancer	0.00242	0.00933	CcSEcCtD
Carfilzomib—Decreased appetite—Lomustine—brain cancer	0.00233	0.00898	CcSEcCtD
Carfilzomib—Hepatic failure—Temozolomide—brain cancer	0.00233	0.00897	CcSEcCtD
Carfilzomib—Hyponatraemia—Carmustine—brain cancer	0.00217	0.00838	CcSEcCtD
Carfilzomib—Neutropenia—Hydroxyurea—brain cancer	0.00216	0.00834	CcSEcCtD
Carfilzomib—Chills—Procarbazine—brain cancer	0.00215	0.00828	CcSEcCtD
Carfilzomib—Body temperature increased—Lomustine—brain cancer	0.00212	0.00816	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Hydroxyurea—brain cancer	0.00202	0.0078	CcSEcCtD
Carfilzomib—Sepsis—Etoposide—brain cancer	0.002	0.00772	CcSEcCtD
Carfilzomib—Hypokalaemia—Carmustine—brain cancer	0.00197	0.0076	CcSEcCtD
Carfilzomib—Anaemia—Procarbazine—brain cancer	0.00193	0.00743	CcSEcCtD
Carfilzomib—Hypokalaemia—Temozolomide—brain cancer	0.0019	0.00734	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Temozolomide—brain cancer	0.00188	0.00726	CcSEcCtD
Carfilzomib—Leukopenia—Procarbazine—brain cancer	0.00187	0.00719	CcSEcCtD
Carfilzomib—ABCB1—blood vessel—brain cancer	0.00186	0.0103	CbGeAlD
Carfilzomib—Cardiac failure congestive—Etoposide—brain cancer	0.00185	0.00712	CcSEcCtD
Carfilzomib—Cough—Procarbazine—brain cancer	0.00182	0.00701	CcSEcCtD
Carfilzomib—Hypertension—Procarbazine—brain cancer	0.0018	0.00694	CcSEcCtD
Carfilzomib—Arthralgia—Procarbazine—brain cancer	0.00177	0.00684	CcSEcCtD
Carfilzomib—Neutropenia—Carmustine—brain cancer	0.00175	0.00675	CcSEcCtD
Carfilzomib—Vomiting—Lomustine—brain cancer	0.0017	0.00657	CcSEcCtD
Carfilzomib—Neutropenia—Temozolomide—brain cancer	0.00169	0.00652	CcSEcCtD
Carfilzomib—Infection—Procarbazine—brain cancer	0.00169	0.00651	CcSEcCtD
Carfilzomib—Hyperglycaemia—Carmustine—brain cancer	0.00169	0.00651	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Temozolomide—brain cancer	0.00168	0.00648	CcSEcCtD
Carfilzomib—Pneumonia—Carmustine—brain cancer	0.00168	0.00647	CcSEcCtD
Carfilzomib—Thrombocytopenia—Procarbazine—brain cancer	0.00167	0.00642	CcSEcCtD
Carfilzomib—Chills—Hydroxyurea—brain cancer	0.00166	0.00641	CcSEcCtD
Carfilzomib—Renal failure—Carmustine—brain cancer	0.00164	0.00632	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Carmustine—brain cancer	0.00164	0.0063	CcSEcCtD
Carfilzomib—Hyperglycaemia—Temozolomide—brain cancer	0.00163	0.00629	CcSEcCtD
Carfilzomib—Pneumonia—Temozolomide—brain cancer	0.00162	0.00625	CcSEcCtD
Carfilzomib—Anorexia—Procarbazine—brain cancer	0.00162	0.00625	CcSEcCtD
Carfilzomib—Cardiac arrest—Etoposide—brain cancer	0.00159	0.00614	CcSEcCtD
Carfilzomib—Nausea—Lomustine—brain cancer	0.00159	0.00613	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Temozolomide—brain cancer	0.00158	0.00609	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Procarbazine—brain cancer	0.00155	0.00597	CcSEcCtD
Carfilzomib—Insomnia—Procarbazine—brain cancer	0.00154	0.00593	CcSEcCtD
Carfilzomib—Anaemia—Hydroxyurea—brain cancer	0.00149	0.00575	CcSEcCtD
Carfilzomib—Hypoaesthesia—Carmustine—brain cancer	0.00149	0.00574	CcSEcCtD
Carfilzomib—Decreased appetite—Procarbazine—brain cancer	0.00148	0.0057	CcSEcCtD
Carfilzomib—Oedema peripheral—Carmustine—brain cancer	0.00148	0.00569	CcSEcCtD
Carfilzomib—Fatigue—Procarbazine—brain cancer	0.00147	0.00565	CcSEcCtD
Carfilzomib—Constipation—Procarbazine—brain cancer	0.00145	0.00561	CcSEcCtD
Carfilzomib—Pain—Procarbazine—brain cancer	0.00145	0.00561	CcSEcCtD
Carfilzomib—Leukopenia—Hydroxyurea—brain cancer	0.00144	0.00557	CcSEcCtD
Carfilzomib—Hypoaesthesia—Temozolomide—brain cancer	0.00144	0.00555	CcSEcCtD
Carfilzomib—Oedema peripheral—Temozolomide—brain cancer	0.00143	0.0055	CcSEcCtD
Carfilzomib—Neutropenia—Etoposide—brain cancer	0.00135	0.00522	CcSEcCtD
Carfilzomib—Body temperature increased—Procarbazine—brain cancer	0.00134	0.00518	CcSEcCtD
Carfilzomib—Cardiac disorder—Temozolomide—brain cancer	0.00134	0.00518	CcSEcCtD
Carfilzomib—Infection—Hydroxyurea—brain cancer	0.00131	0.00504	CcSEcCtD
Carfilzomib—Chills—Temozolomide—brain cancer	0.0013	0.00501	CcSEcCtD
Carfilzomib—Pneumonia—Etoposide—brain cancer	0.0013	0.005	CcSEcCtD
Carfilzomib—Thrombocytopenia—Hydroxyurea—brain cancer	0.00129	0.00497	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Etoposide—brain cancer	0.00127	0.0049	CcSEcCtD
Carfilzomib—Renal failure—Etoposide—brain cancer	0.00127	0.00489	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Etoposide—brain cancer	0.00126	0.00488	CcSEcCtD
Carfilzomib—Back pain—Carmustine—brain cancer	0.00126	0.00486	CcSEcCtD
Carfilzomib—Anorexia—Hydroxyurea—brain cancer	0.00125	0.00484	CcSEcCtD
Carfilzomib—Asthenia—Procarbazine—brain cancer	0.00122	0.0047	CcSEcCtD
Carfilzomib—Back pain—Temozolomide—brain cancer	0.00122	0.0047	CcSEcCtD
Carfilzomib—Anaemia—Carmustine—brain cancer	0.00121	0.00465	CcSEcCtD
Carfilzomib—Dyspnoea—Hydroxyurea—brain cancer	0.00117	0.00452	CcSEcCtD
Carfilzomib—Leukopenia—Carmustine—brain cancer	0.00117	0.0045	CcSEcCtD
Carfilzomib—Anaemia—Temozolomide—brain cancer	0.00116	0.00449	CcSEcCtD
Carfilzomib—Diarrhoea—Procarbazine—brain cancer	0.00116	0.00449	CcSEcCtD
Carfilzomib—Hypoaesthesia—Etoposide—brain cancer	0.00115	0.00444	CcSEcCtD
Carfilzomib—Decreased appetite—Hydroxyurea—brain cancer	0.00114	0.00441	CcSEcCtD
Carfilzomib—Fatigue—Hydroxyurea—brain cancer	0.00113	0.00437	CcSEcCtD
Carfilzomib—Leukopenia—Temozolomide—brain cancer	0.00113	0.00435	CcSEcCtD
Carfilzomib—Hypertension—Carmustine—brain cancer	0.00113	0.00434	CcSEcCtD
Carfilzomib—Pain—Hydroxyurea—brain cancer	0.00113	0.00434	CcSEcCtD
Carfilzomib—Constipation—Hydroxyurea—brain cancer	0.00113	0.00434	CcSEcCtD
Carfilzomib—Dizziness—Procarbazine—brain cancer	0.00112	0.00434	CcSEcCtD
Carfilzomib—Cough—Temozolomide—brain cancer	0.0011	0.00424	CcSEcCtD
Carfilzomib—Hypertension—Temozolomide—brain cancer	0.00109	0.00419	CcSEcCtD
Carfilzomib—Vomiting—Procarbazine—brain cancer	0.00108	0.00417	CcSEcCtD
Carfilzomib—Cardiac disorder—Etoposide—brain cancer	0.00107	0.00414	CcSEcCtD
Carfilzomib—Arthralgia—Temozolomide—brain cancer	0.00107	0.00414	CcSEcCtD
Carfilzomib—Headache—Procarbazine—brain cancer	0.00107	0.00411	CcSEcCtD
Carfilzomib—Infection—Carmustine—brain cancer	0.00106	0.00408	CcSEcCtD
Carfilzomib—Thrombocytopenia—Carmustine—brain cancer	0.00104	0.00402	CcSEcCtD
Carfilzomib—Body temperature increased—Hydroxyurea—brain cancer	0.00104	0.00401	CcSEcCtD
Carfilzomib—Chills—Etoposide—brain cancer	0.00104	0.00401	CcSEcCtD
Carfilzomib—Infection—Temozolomide—brain cancer	0.00102	0.00394	CcSEcCtD
Carfilzomib—Anorexia—Carmustine—brain cancer	0.00101	0.00391	CcSEcCtD
Carfilzomib—Nausea—Procarbazine—brain cancer	0.00101	0.00389	CcSEcCtD
Carfilzomib—Thrombocytopenia—Temozolomide—brain cancer	0.00101	0.00388	CcSEcCtD
Carfilzomib—Anorexia—Temozolomide—brain cancer	0.00098	0.00378	CcSEcCtD
Carfilzomib—Back pain—Etoposide—brain cancer	0.000975	0.00376	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Carmustine—brain cancer	0.000969	0.00374	CcSEcCtD
Carfilzomib—Muscle spasms—Etoposide—brain cancer	0.000969	0.00374	CcSEcCtD
Carfilzomib—Insomnia—Carmustine—brain cancer	0.000962	0.00371	CcSEcCtD
Carfilzomib—Dyspnoea—Carmustine—brain cancer	0.000949	0.00366	CcSEcCtD
Carfilzomib—Asthenia—Hydroxyurea—brain cancer	0.000944	0.00364	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000937	0.00361	CcSEcCtD
Carfilzomib—Anaemia—Etoposide—brain cancer	0.000932	0.00359	CcSEcCtD
Carfilzomib—Insomnia—Temozolomide—brain cancer	0.00093	0.00359	CcSEcCtD
Carfilzomib—Decreased appetite—Carmustine—brain cancer	0.000925	0.00357	CcSEcCtD
Carfilzomib—Dyspnoea—Temozolomide—brain cancer	0.000917	0.00353	CcSEcCtD
Carfilzomib—Constipation—Carmustine—brain cancer	0.00091	0.00351	CcSEcCtD
Carfilzomib—Pain—Carmustine—brain cancer	0.00091	0.00351	CcSEcCtD
Carfilzomib—Leukopenia—Etoposide—brain cancer	0.000903	0.00348	CcSEcCtD
Carfilzomib—ABCB1—telencephalon—brain cancer	0.000901	0.00502	CbGeAlD
Carfilzomib—Diarrhoea—Hydroxyurea—brain cancer	0.000901	0.00347	CcSEcCtD
Carfilzomib—Decreased appetite—Temozolomide—brain cancer	0.000894	0.00345	CcSEcCtD
Carfilzomib—Fatigue—Temozolomide—brain cancer	0.000887	0.00342	CcSEcCtD
Carfilzomib—Cough—Etoposide—brain cancer	0.00088	0.00339	CcSEcCtD
Carfilzomib—Pain—Temozolomide—brain cancer	0.000879	0.00339	CcSEcCtD
Carfilzomib—Constipation—Temozolomide—brain cancer	0.000879	0.00339	CcSEcCtD
Carfilzomib—Hypertension—Etoposide—brain cancer	0.00087	0.00336	CcSEcCtD
Carfilzomib—Dizziness—Hydroxyurea—brain cancer	0.00087	0.00336	CcSEcCtD
Carfilzomib—Body temperature increased—Carmustine—brain cancer	0.000841	0.00324	CcSEcCtD
Carfilzomib—Vomiting—Hydroxyurea—brain cancer	0.000837	0.00323	CcSEcCtD
Carfilzomib—Headache—Hydroxyurea—brain cancer	0.000825	0.00318	CcSEcCtD
Carfilzomib—Infection—Etoposide—brain cancer	0.000817	0.00315	CcSEcCtD
Carfilzomib—Body temperature increased—Temozolomide—brain cancer	0.000813	0.00313	CcSEcCtD
Carfilzomib—Thrombocytopenia—Etoposide—brain cancer	0.000806	0.00311	CcSEcCtD
Carfilzomib—Anorexia—Etoposide—brain cancer	0.000784	0.00302	CcSEcCtD
Carfilzomib—Nausea—Hydroxyurea—brain cancer	0.000782	0.00301	CcSEcCtD
Carfilzomib—Asthenia—Carmustine—brain cancer	0.000763	0.00294	CcSEcCtD
Carfilzomib—ABCB1—gonad—brain cancer	0.000752	0.00419	CbGeAlD
Carfilzomib—Asthenia—Temozolomide—brain cancer	0.000738	0.00284	CcSEcCtD
Carfilzomib—ABCB1—pituitary gland—brain cancer	0.000734	0.00409	CbGeAlD
Carfilzomib—Dyspnoea—Etoposide—brain cancer	0.000734	0.00283	CcSEcCtD
Carfilzomib—Diarrhoea—Carmustine—brain cancer	0.000728	0.00281	CcSEcCtD
Carfilzomib—Decreased appetite—Etoposide—brain cancer	0.000715	0.00276	CcSEcCtD
Carfilzomib—Fatigue—Etoposide—brain cancer	0.000709	0.00273	CcSEcCtD
Carfilzomib—ABCB1—medulla oblongata—brain cancer	0.000708	0.00394	CbGeAlD
Carfilzomib—Dizziness—Carmustine—brain cancer	0.000704	0.00271	CcSEcCtD
Carfilzomib—Pain—Etoposide—brain cancer	0.000704	0.00271	CcSEcCtD
Carfilzomib—Constipation—Etoposide—brain cancer	0.000704	0.00271	CcSEcCtD
Carfilzomib—Diarrhoea—Temozolomide—brain cancer	0.000704	0.00271	CcSEcCtD
Carfilzomib—Dizziness—Temozolomide—brain cancer	0.00068	0.00262	CcSEcCtD
Carfilzomib—Vomiting—Carmustine—brain cancer	0.000677	0.00261	CcSEcCtD
Carfilzomib—Headache—Carmustine—brain cancer	0.000667	0.00257	CcSEcCtD
Carfilzomib—Vomiting—Temozolomide—brain cancer	0.000654	0.00252	CcSEcCtD
Carfilzomib—Body temperature increased—Etoposide—brain cancer	0.00065	0.00251	CcSEcCtD
Carfilzomib—ABCB1—midbrain—brain cancer	0.000647	0.0036	CbGeAlD
Carfilzomib—Headache—Temozolomide—brain cancer	0.000644	0.00248	CcSEcCtD
Carfilzomib—Nausea—Carmustine—brain cancer	0.000632	0.00244	CcSEcCtD
Carfilzomib—ABCB1—spinal cord—brain cancer	0.000632	0.00352	CbGeAlD
Carfilzomib—Nausea—Temozolomide—brain cancer	0.000611	0.00235	CcSEcCtD
Carfilzomib—Asthenia—Etoposide—brain cancer	0.00059	0.00228	CcSEcCtD
Carfilzomib—ABCB1—endocrine gland—brain cancer	0.000569	0.00317	CbGeAlD
Carfilzomib—Diarrhoea—Etoposide—brain cancer	0.000563	0.00217	CcSEcCtD
Carfilzomib—ABCB1—head—brain cancer	0.000561	0.00313	CbGeAlD
Carfilzomib—Dizziness—Etoposide—brain cancer	0.000544	0.0021	CcSEcCtD
Carfilzomib—Vomiting—Etoposide—brain cancer	0.000523	0.00202	CcSEcCtD
Carfilzomib—Headache—Etoposide—brain cancer	0.000515	0.00199	CcSEcCtD
Carfilzomib—ABCB1—central nervous system—brain cancer	0.000512	0.00285	CbGeAlD
Carfilzomib—ABCB1—cerebellum—brain cancer	0.000501	0.00279	CbGeAlD
Carfilzomib—Nausea—Etoposide—brain cancer	0.000489	0.00188	CcSEcCtD
Carfilzomib—ABCB1—brain—brain cancer	0.000407	0.00226	CbGeAlD
Carfilzomib—PSMB5—Adaptive Immune System—RELA—brain cancer	9.12e-05	0.000169	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—RELA—brain cancer	9.12e-05	0.000169	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—ERBB2—brain cancer	9.06e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—ERBB2—brain cancer	9.06e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—ERBB2—brain cancer	9.06e-05	0.000168	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PDGFRA—brain cancer	9e-05	0.000167	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—RELA—brain cancer	8.99e-05	0.000166	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—ERBB2—brain cancer	8.93e-05	0.000165	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HES1—brain cancer	8.85e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HES1—brain cancer	8.85e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HES1—brain cancer	8.85e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—CCND1—brain cancer	8.74e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—CCND1—brain cancer	8.74e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—CCND1—brain cancer	8.74e-05	0.000162	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HES1—brain cancer	8.73e-05	0.000162	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	8.66e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—APC—brain cancer	8.62e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—CCND1—brain cancer	8.62e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—APC—brain cancer	8.58e-05	0.000159	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PDGFRA—brain cancer	8.43e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PDGFRA—brain cancer	8.43e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PDGFRA—brain cancer	8.43e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PDGFRA—brain cancer	8.31e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—EGFR—brain cancer	8.29e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—EGFR—brain cancer	8.25e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HES1—brain cancer	8.18e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HES1—brain cancer	8.14e-05	0.000151	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IRS2—brain cancer	8.01e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IRS2—brain cancer	8.01e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IRS2—brain cancer	8.01e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IRS2—brain cancer	7.9e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle, Mitotic—MYC—brain cancer	7.84e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle, Mitotic—MYC—brain cancer	7.84e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle, Mitotic—MYC—brain cancer	7.84e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PDGFRA—brain cancer	7.79e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PDGFRA—brain cancer	7.75e-05	0.000144	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle, Mitotic—MYC—brain cancer	7.73e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—brain cancer	7.6e-05	0.000141	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NOTCH2—brain cancer	7.56e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NOTCH2—brain cancer	7.56e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NOTCH2—brain cancer	7.56e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SPP1—brain cancer	7.56e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—brain cancer	7.56e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SPP1—brain cancer	7.52e-05	0.000139	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NOTCH2—brain cancer	7.45e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IRS2—brain cancer	7.4e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IRS2—brain cancer	7.4e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IRS2—brain cancer	7.4e-05	0.000137	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—RELA—brain cancer	7.3e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IRS2—brain cancer	7.3e-05	0.000135	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—RELA—brain cancer	7.26e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—ERBB2—brain cancer	7.25e-05	0.000134	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	7.23e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CG—brain cancer	7.22e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—ERBB2—brain cancer	7.22e-05	0.000134	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VAV1—brain cancer	7.21e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VAV1—brain cancer	7.21e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VAV1—brain cancer	7.21e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CG—brain cancer	7.19e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VAV1—brain cancer	7.11e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—MYC—brain cancer	7.01e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—MYC—brain cancer	7.01e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—MYC—brain cancer	7.01e-05	0.00013	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—MYC—brain cancer	6.91e-05	0.000128	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IRS2—brain cancer	6.84e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IRS2—brain cancer	6.8e-05	0.000126	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	6.72e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—ERBB2—brain cancer	6.7e-05	0.000124	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—ERBB2—brain cancer	6.66e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL2—brain cancer	6.57e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL2—brain cancer	6.54e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—APC—brain cancer	6.54e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—APC—brain cancer	6.54e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—APC—brain cancer	6.54e-05	0.000121	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—APC—brain cancer	6.44e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—CTNNB1—brain cancer	6.35e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CTNNB1—brain cancer	6.31e-05	0.000117	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—EGFR—brain cancer	6.28e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—EGFR—brain cancer	6.28e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—EGFR—brain cancer	6.28e-05	0.000116	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HES1—brain cancer	6.2e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HES1—brain cancer	6.2e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HES1—brain cancer	6.2e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—EGFR—brain cancer	6.19e-05	0.000115	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HES1—brain cancer	6.11e-05	0.000113	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2C9—brain cancer	6.07e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CG—brain cancer	6.04e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—APC—brain cancer	6.04e-05	0.000112	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—APC—brain cancer	6.01e-05	0.000111	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CG—brain cancer	6.01e-05	0.000111	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	5.94e-05	0.00011	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PDGFRA—brain cancer	5.9e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PDGFRA—brain cancer	5.9e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PDGFRA—brain cancer	5.9e-05	0.000109	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	5.88e-05	0.000109	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—CTNNB1—brain cancer	5.86e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CTNNB1—brain cancer	5.83e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PDGFRA—brain cancer	5.82e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—brain cancer	5.76e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—brain cancer	5.76e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—brain cancer	5.76e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SPP1—brain cancer	5.73e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SPP1—brain cancer	5.73e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SPP1—brain cancer	5.73e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—brain cancer	5.68e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SPP1—brain cancer	5.65e-05	0.000105	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—STAT3—brain cancer	5.53e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—RELA—brain cancer	5.53e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—RELA—brain cancer	5.53e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—RELA—brain cancer	5.53e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—STAT3—brain cancer	5.5e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ERBB2—brain cancer	5.5e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ERBB2—brain cancer	5.5e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ERBB2—brain cancer	5.5e-05	0.000102	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CG—brain cancer	5.47e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CG—brain cancer	5.47e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CG—brain cancer	5.47e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—RELA—brain cancer	5.45e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ERBB2—brain cancer	5.42e-05	0.0001	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CG—brain cancer	5.4e-05	9.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IRS2—brain cancer	5.18e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IRS2—brain cancer	5.18e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IRS2—brain cancer	5.18e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	5.18e-05	9.59e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—BSG—brain cancer	5.16e-05	9.56e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—MYC—brain cancer	5.11e-05	9.46e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IRS2—brain cancer	5.11e-05	9.46e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—STAT3—brain cancer	5.11e-05	9.45e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—MYC—brain cancer	5.09e-05	9.42e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—STAT3—brain cancer	5.08e-05	9.41e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—ERBB2—brain cancer	5.07e-05	9.4e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—ERBB2—brain cancer	5.07e-05	9.4e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—ERBB2—brain cancer	5.07e-05	9.4e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—EGFR—brain cancer	5.03e-05	9.31e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—ERBB2—brain cancer	5e-05	9.26e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—EGFR—brain cancer	5e-05	9.26e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL2—brain cancer	4.98e-05	9.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL2—brain cancer	4.98e-05	9.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL2—brain cancer	4.98e-05	9.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL2—brain cancer	4.91e-05	9.09e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CTNNB1—brain cancer	4.81e-05	8.9e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CTNNB1—brain cancer	4.81e-05	8.9e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CTNNB1—brain cancer	4.81e-05	8.9e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	4.76e-05	8.82e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—MYC—brain cancer	4.75e-05	8.79e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CTNNB1—brain cancer	4.74e-05	8.78e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—MYC—brain cancer	4.72e-05	8.74e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—RELA—brain cancer	4.72e-05	8.74e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—RELA—brain cancer	4.7e-05	8.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—ERBB2—brain cancer	4.69e-05	8.68e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—ERBB2—brain cancer	4.67e-05	8.64e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	4.66e-05	8.63e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—EGFR—brain cancer	4.64e-05	8.59e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—EGFR—brain cancer	4.62e-05	8.55e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—APC—brain cancer	4.58e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CG—brain cancer	4.58e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CG—brain cancer	4.58e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—APC—brain cancer	4.58e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CG—brain cancer	4.58e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—APC—brain cancer	4.58e-05	8.47e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CG—brain cancer	4.51e-05	8.35e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APC—brain cancer	4.51e-05	8.35e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—IDH1—brain cancer	4.44e-05	8.22e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CTNNB1—brain cancer	4.44e-05	8.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CTNNB1—brain cancer	4.44e-05	8.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CTNNB1—brain cancer	4.44e-05	8.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CTNNB1—brain cancer	4.38e-05	8.1e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL2—brain cancer	4.25e-05	7.87e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL2—brain cancer	4.23e-05	7.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—brain cancer	4.19e-05	7.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—brain cancer	4.19e-05	7.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—brain cancer	4.19e-05	7.76e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CCND1—brain cancer	4.14e-05	7.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—brain cancer	4.13e-05	7.65e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CCND1—brain cancer	4.12e-05	7.63e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CTNNB1—brain cancer	4.1e-05	7.6e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CTNNB1—brain cancer	4.08e-05	7.56e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	3.91e-05	7.24e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—brain cancer	3.87e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—brain cancer	3.87e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—brain cancer	3.87e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—brain cancer	3.87e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—brain cancer	3.87e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—brain cancer	3.87e-05	7.17e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—brain cancer	3.82e-05	7.07e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—brain cancer	3.82e-05	7.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—brain cancer	3.81e-05	7.05e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—brain cancer	3.81e-05	7.05e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—brain cancer	3.81e-05	7.05e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—brain cancer	3.76e-05	6.95e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—brain cancer	3.61e-05	6.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—brain cancer	3.6e-05	6.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—brain cancer	3.6e-05	6.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—brain cancer	3.6e-05	6.66e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—brain cancer	3.59e-05	6.65e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—RELA—brain cancer	3.58e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—RELA—brain cancer	3.58e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—RELA—brain cancer	3.58e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—brain cancer	3.58e-05	6.62e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—brain cancer	3.56e-05	6.59e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—brain cancer	3.55e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—brain cancer	3.55e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—brain cancer	3.55e-05	6.58e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—brain cancer	3.55e-05	6.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—RELA—brain cancer	3.53e-05	6.53e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—brain cancer	3.52e-05	6.51e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—brain cancer	3.52e-05	6.51e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—brain cancer	3.52e-05	6.51e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—ENO2—brain cancer	3.51e-05	6.5e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—brain cancer	3.5e-05	6.49e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—brain cancer	3.47e-05	6.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—brain cancer	3.32e-05	6.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—brain cancer	3.31e-05	6.12e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—brain cancer	3.25e-05	6.02e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—brain cancer	3.23e-05	5.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—brain cancer	3.22e-05	5.96e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—brain cancer	3.22e-05	5.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—brain cancer	3.22e-05	5.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—brain cancer	3.18e-05	5.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—brain cancer	3.14e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—brain cancer	3.14e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—brain cancer	3.14e-05	5.81e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—brain cancer	3.11e-05	5.76e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—brain cancer	3.11e-05	5.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—brain cancer	3.11e-05	5.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—brain cancer	3.1e-05	5.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—brain cancer	3.07e-05	5.68e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—brain cancer	2.74e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—brain cancer	2.74e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—brain cancer	2.74e-05	5.07e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—brain cancer	2.73e-05	5.05e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—brain cancer	2.72e-05	5.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—brain cancer	2.71e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—brain cancer	2.71e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—brain cancer	2.71e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—brain cancer	2.7e-05	5e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—brain cancer	2.67e-05	4.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—brain cancer	2.52e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—brain cancer	2.52e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—brain cancer	2.52e-05	4.66e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—brain cancer	2.48e-05	4.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—brain cancer	2.46e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—brain cancer	2.46e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—brain cancer	2.46e-05	4.56e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—brain cancer	2.43e-05	4.5e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—brain cancer	2.07e-05	3.83e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—brain cancer	2.07e-05	3.83e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—brain cancer	2.07e-05	3.83e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—brain cancer	2.04e-05	3.78e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—brain cancer	1.61e-05	2.98e-05	CbGpPWpGaD
